Pregled bibliografske jedinice broj: 726375
Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2- negative locally recurrent/metastacic breast cancer (LR/MBC)
Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2- negative locally recurrent/metastacic breast cancer (LR/MBC) // Annals of Oncology
Ujedinjeno Kraljevstvo, 2014. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 726375 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2- negative locally recurrent/metastacic breast cancer (LR/MBC)
Autori
Von Minckwitz, G ; Puglisi, F ; Cortes, J ; Vrdoljak, E ; Marschner, N ; Zielinski, C ; Villanueva CB ;
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
Annals of Oncology
Mjesto i datum
Ujedinjeno Kraljevstvo, 2014
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
breast cancer; metastatic
Sažetak
Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2-negative locally recurrent/metastacic breast cancer (LR/MBC)
Izvorni jezik
Engleski
